Nautilus Biotechnolgy, Inc. Common Stock (NAUT) is a publicly traded Healthcare sector company. As of May 21, 2026, NAUT trades at $2.38 with a market cap of $299.91M and a P/E ratio of -5.01. NAUT moved +0.00% today. Year to date, NAUT is +25.93%; over the trailing twelve months it is +189.54%. Its 52-week range spans $0.62 to $4.31. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces NAUT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nautilus Launches Tau Early Access Program, Cuts Q1 Expenses 14%: Nautilus Biotechnology cut Q1 operating expenses by 14% to $16.1 million and narrowed its net loss to $14.7 million while holding $143.4 million in cash and investments as of March 31, 2026. The company launched its Tau proteoform Early Access Program and appointed Amber Faust as VP of Global Sales.
| Metric | Value |
|---|---|
| Price | $2.38 |
| Market Cap | $299.91M |
| P/E Ratio | -5.01 |
| EPS | $-0.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.31 |
| 52-Week Low | $0.62 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-59.00M |
| Gross Margin | 0.00% |
2 analysts cover NAUT: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.